Literature DB >> 35605992

Physiologic Targets and Modes of Action for CBL0137, a Lead for Human African Trypanosomiasis Drug Development.

Carlos E Sanz-Rodriguez1, Benjamin Hoffman1, Paul J Guyett1, Andrei Purmal2, Baljinder Singh3, Michael Pollastri3, Kojo Mensa-Wilmot4.   

Abstract

CBL0137 is a lead drug for human African trypanosomiasis, caused by Trypanosoma brucei Herein, we use a four-step strategy to (a) identify physiologic targets and (b) determine modes of molecular action of CBL0137 in the trypanosome. First, we identified fourteen CBL0137-binding proteins using affinity chromatography. Second, we developed hypotheses of molecular modes of action, using predicted functions of CBL0137-binding proteins as guides. Third, we documented effects of CBL0137 on molecular pathways in the trypanosome. Fourth, we identified physiologic targets of the drug, by knocking down genes encoding CBL0137-binding proteins and comparing their molecular effects to those obtained when trypanosomes were treated with CBL0137. CBL0137-binding proteins included glycolysis enzymes (aldolase, glyceraldehyde-3-phosphate dehydrogenase, phosphofructokinase, phosphoglycerate kinase), and DNA-binding proteins (UMSBP2, RPA1, RPA2). In chemical biology studies CBL0137 did not reduce ATP level in the trypanosome, ruling out glycolysis enzymes as crucial targets for the drug. Thus, many CBL0137-binding proteins are not physiological targets of the drug. Instead, CBL0137 inhibited (i) nucleus mitosis, (ii) nuclear DNA replication, and (iii) polypeptide synthesis as the first carbazole inhibitor of eukaryote translation. RNAi against RPA1 inhibited both DNA synthesis and mitosis, whereas RPA2 knockdown inhibited mitosis, consistent with both proteins being physiologic targets of CBL0137. Principles used here to distinguish drug-binding proteins from physiological targets of CBL0137 can be deployed with different drugs in other biological systems. Significance Statement To distinguish drug-binding proteins from physiologic targets in the African trypanosome we devised and executed a multi-disciplinary approach involving biochemical, genetic, cell, and chemical biology experiments. The strategy we employed can be used for drugs in other biological systems.
Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Keywords:  Protein targets; drug discovery; molecular drug targeting

Year:  2022        PMID: 35605992      PMCID: PMC9341264          DOI: 10.1124/molpharm.121.000430

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.054


  89 in total

1.  Phenotypic Screening Using Mouse and Human Stem Cell-Based Models of Neuroinflammation and Gene Expression Analysis to Study Drug Responses.

Authors:  Masin Abo-Rady; Jessica Bellmann; Michael Glatza; Lara Marrone; Lydia Reinhardt; Santiago Tena; Jared Sterneckert
Journal:  Methods Mol Biol       Date:  2019

2.  Phenotypic screening as a strategic component of drug discovery programs targeting novel antiparasitic and antimycobacterial agents: an editorial.

Authors:  John A Butera
Journal:  J Med Chem       Date:  2013-08-27       Impact factor: 7.446

Review 3.  How were new medicines discovered?

Authors:  David C Swinney; Jason Anthony
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

4.  Fexinidazole: A New Drug for African Sleeping Sickness on the Horizon.

Authors:  Michael P Pollastri
Journal:  Trends Parasitol       Date:  2017-12-20

5.  Activity-Based Kinome Profiling Using Chemical Proteomics and ATP Acyl Phosphates.

Authors:  Caroline E Franks; Ku-Lung Hsu
Journal:  Curr Protoc Chem Biol       Date:  2019-09

6.  The F1-ATP synthase complex in bloodstream stage trypanosomes has an unusual and essential function.

Authors:  Achim Schnaufer; G Desmond Clark-Walker; Alodie G Steinberg; Ken Stuart
Journal:  EMBO J       Date:  2005-11-17       Impact factor: 11.598

7.  Rfc4 interacts with Rpa1 and is required for both DNA replication and DNA damage checkpoints in Saccharomyces cerevisiae.

Authors:  H S Kim; S J Brill
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

8.  RPA complexes in Caenorhabditis elegans meiosis; unique roles in replication, meiotic recombination and apoptosis.

Authors:  Adam Hefel; Masayoshi Honda; Nicholas Cronin; Kailey Harrell; Pooja Patel; Maria Spies; Sarit Smolikove
Journal:  Nucleic Acids Res       Date:  2021-02-26       Impact factor: 16.971

9.  Genomic and Proteomic Studies on the Mode of Action of Oxaboroles against the African Trypanosome.

Authors:  Deuan C Jones; Bernardo J Foth; Michael D Urbaniak; Stephen Patterson; Han B Ong; Matthew Berriman; Alan H Fairlamb
Journal:  PLoS Negl Trop Dis       Date:  2015-12-18

10.  Anilinoquinoline based inhibitors of trypanosomatid proliferation.

Authors:  Lori Ferrins; Amrita Sharma; Sarah M Thomas; Naimee Mehta; Jessey Erath; Scott Tanghe; Susan E Leed; Ana Rodriguez; Kojo Mensa-Wilmot; Richard J Sciotti; Kirsten Gillingwater; Michael P Pollastri
Journal:  PLoS Negl Trop Dis       Date:  2018-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.